Brief: Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results Of Imsidolimab (Il-36R)

AnaptysBio

09/10/2023 13:23

Oct 9 (Reuters) - AnaptysBio Inc  ANAB.O :
    * ANAPTYS ANNOUNCES POSITIVE TOP-LINE PHASE 3 CLINICAL TRIAL
RESULTS OF IMSIDOLIMAB (IL-36R) IN GENERALIZED PUSTULAR
PSORIASIS (GPP)
    * ANAPTYSBIO INC - PLAN TO PRESENT COMPREHENSIVE DATA FROM
GEMINI-1 AND TOP-LINE GEMINI-2 RESULTS AT A MEDICAL MEETING IN
H2 2024
    * ANAPTYSBIO INC - INTEND TO OUT-LICENSE IMSIDOLIMAB IN 2024
    * ANAPTYSBIO INC - DEMONSTRATED FAVORABLE SAFETY AND
TOLERABILITY
WITH NO SAES, LOW INCIDENCE AND NO INCREASE OF INFECTIONS
VERSUS. PLACEBO
    * ANAPTYSBIO INC - TOP-LINE DATA ALSO DEMONSTRATE A
FAVORABLE
SAFETY AND TOLERABILITY PROFILE.
    * ANAPTYSBIO INC - SEES FILING A BIOLOGICS LICENSE
APPLICATION
(BLA) WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) BY Q3 2024

Source text for Eikon:  ID:nGNX3cZWlj 
Further company coverage:  ANAB.O 

 ((Reuters.Briefs@thomsonreuters.com))